Table 1.
Baseline patient, tumor, and treatment characteristics, n = 96 1.
| Characteristic. | No. (%) |
|---|---|
| Median age, range | 59 (55–67) |
| Gender | |
| Female | 28 (29) |
| Male | 68 (71) |
| Race | |
| White | 90 (94) |
| Black | 2 (2.1) |
| Asian | 1 (1.0) |
| Other | 3 (3.1) |
| IMDC Risk Category | |
| Favorable | 20 (21) |
| Intermediate | 56 (58) |
| Poor | 9 (9) |
| Indeterminate | 11 (12) |
| Primary tumor size (cm) | 8.2 (6.0, 11.0) |
| ISUP Grade | |
| 2 | 11 (11) |
| 3 | 60 (62) |
| 4 | 25 (26) |
| Sarcomatoid Variant | |
| No | 87 (91) |
| Yes | 9 (9.4) |
| Rhabdoid Variant | |
| No | 88 (92) |
| Yes | 8 (8.3) |
| First Line Therapy | |
| IT | 51 (53) |
| TT | 42 (44) |
| Both | 3 (3.1) |
| Response Category | |
| IT Resistance | 25 (32) |
| IT Response | 18 (23) |
| IT Indeterminate | 8 (8.3) |
| TT Resistance | 9 (9.4) |
| TT Response | 27 (28) |
| TT Indeterminate | 6 (6.3) |
1 Statistics presented: median (IQR); Abbreviations: IMDC, International Metastatic RCC Database Consortium; ISUP, International Society of Urologic Pathologists; IT, immunotherapy; TT, targeted therapy.